$OPK News
Last published 1w ago
- 1w agoOPKOPKO HEALTH, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoOPKOPKO Health Reports Third Quarter 2026 Business Highlights and Financial ResultsGlobeNewswireMIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30,
- 2w agoOPKOPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswireMIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ:OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026
- 2w agoOPKOPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for AcromegalyGlobeNewswireKIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ:OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial
- 3w agoLHOPKLabcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthPR NewswireAcquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwideBURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ --
- 2mo agoOPKOPKO Health to Participate in the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewswireMIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets,
- 3mo agoOPKKKROPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty InterestsGlobeNewswireMIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an
- 3mo agoCOCPOPKCocrystal Pharma Announces $5 Million Private Placement with OPKO HealthGlobeNewswireLongtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP)
- 3mo agoOPKOPKO Health Reports Second Quarter 2026 Business Highlights and Financial ResultsGlobeNewswireMIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ:OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global
- 3mo agoOPKOPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026GlobeNewswireMIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ:OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global
- 4mo agoENTXOPKEntera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026GlobeNewswireEB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618,
- 4mo agoOPKPreclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026GlobeNewswireMIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting. The
- 6mo agoOPKOPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical StudiesGlobeNewswireMultispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will be presented at the American Society of Gene & Cell Therapy (ASGCT)
- 6mo agoOPKOPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater ChinaGlobeNewswireMIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics
- 6mo agoOPKBioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital PlatformGlobeNewswireELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of
- 6mo agoOPKOPKO Health Reports First Quarter 2026 Business Highlights and Financial ResultsGlobeNewswireMIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026
- 6mo agoOPKOPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell LymphomasGlobeNewswirePatients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of Hematology (ASH) Annual
- 6mo agoOPKOPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026GlobeNewswireMIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on
- 7mo agoOPKOPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19GlobeNewswireWESTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301
- 8mo agoOPKOPKO Health to Participate in the Jefferies Biotech on the Beach SummitGlobeNewswireMIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South
- 8mo agoOPKOPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial ResultsGlobeNewswireMIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance
- 9mo agoOPKOPKO Health to Report Fourth Quarter 2025 Financial Results on February 26GlobeNewswireMIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets
- 9mo agoENTXOPKOPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with HypoparathyroidismGlobeNewswireThis is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to file an
- 10mo agoOPKOPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the
- 11mo agoOPKOPKO Health to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireMIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the
- 12mo agoNXPLOPKBABANextPlat Reports Third Quarter 2025 ResultsPR NewswireNextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and...
- 1y agoOPKOPKO Health Reports Third Quarter 2025 Business Highlights and Financial ResultsGlobeNewswireMIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third
- 1y agoOPKREGNOPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic IndicationsGlobeNewswirePotential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) --
- 1y agoOPKOPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced CancersGlobeNewswireFirst patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28,
- 1y agoOPKOPKO Health to Report Third Quarter 2025 Financial Results on October 29GlobeNewswireMIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial
- 1y agoLHOPKLabcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services BusinessesPR NewswireLabcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational...
- 1y agoOPKOPKO Health, Inc. (OPK) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoOPKOPKO Health Reports Second Quarter 2025 Business Highlights and Financial ResultsGlobeNewswireMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025
- 1y agoOPKOPKO Health to Report Second Quarter 2025 Financial Results on July 31GlobeNewswireMIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on
- 1y agoENTXOPKOPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN CongressGlobeNewswireMIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) ("OPKO") and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that their abstract "First-in-Class Oral GLP-2 Analog for
- 1y agoNXPLOPKNextPlat Issues Interim CEO Update Shareholder LetterPR NewswireNextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and...
- 1y agoOPKOPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity SymposiumGlobeNewswireMIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be
- 1y agoENTXOPKOPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual MeetingGlobeNewswireMIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for
- 1y agoOPKOPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug DevelopmentGlobeNewswireWill provide expertise across ModeX's portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX's promising immunology pipeline includes first-in
- 1y agoOPKOPKO Health to Participate in Two Upcoming Investor ConferencesGlobeNewswireMIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3rd Annual BioConnect
- 1y agoOPKOPKO Health Reports First Quarter 2025 Business Highlights and Financial ResultsGlobeNewswireMIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and
- 1y agoOPKOPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025GlobeNewswireMIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on
- 1y agoOPKOPKO Health Announces $100 Million Increase to its Existing Share Repurchase ProgramGlobeNewswireMIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase
- 1y agoENTXOPKOPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic DisordersGlobeNewswireMIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a
- 1y agoLHOPKLabcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services BusinessesPR NewswireLabcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational...
- 1y agoOPKOPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial ResultsGlobeNewswireMIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of
- 1y agoOPKOPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025GlobeNewswireMIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets
- 1y agoOPKOPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at
- 1y agoOPKOPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with MerckGlobeNewswireEpstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel
- 1y agoNXPLOPKNextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online RetailerPR NewswireNextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced a significant expansion of its...